Vaxart, Inc.SEC Filings
|
|
All SEC filings by Vaxart, Inc. (VXRT) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q | Quarterly report | View Diff | Aug 6, 2026 | |
| ARS | Annual report to shareholders | Jun 1, 2026 | ||
| 10-Q | Quarterly report | View Diff | May 7, 2026 | |
| 10-K/A | Annual report | View Diff | Apr 30, 2026 | |
| 10-K | Annual report | View Diff | Mar 12, 2026 | |
| 10-Q | Quarterly report | View Diff | Nov 13, 2025 | |
| 10-Q | Quarterly report | View Diff | Aug 13, 2025 | |
| 10-Q | Quarterly report | View Diff | May 13, 2025 | |
| ARS | Annual report to shareholders | Apr 10, 2025 | ||
| 10-K | Annual report | View Diff | Mar 20, 2025 |
Events
| 8-K | Current report | Aug 25, 2026 | ||
| 8-K | Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results | Aug 6, 2026 | ||
| 8-K | Current report | Jul 28, 2026 | ||
| 8-K | Vaxart Announces Results of Annual Meeting of Stockholders | Jul 17, 2026 | ||
| 8-K | Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill Covid-19 Vaccine | Jul 7, 2026 | ||
| 8-K | Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements | Jul 2, 2026 | ||
| 8-K | Current report | Jun 26, 2026 | ||
| 8-K | Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders | May 19, 2026 | ||
| 8-K | Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results | May 7, 2026 | ||
| 8-K | Vaxart Appoints James Breitmeyer, M.d., Ph.d., to Board of Directors | Apr 23, 2026 |
Registrations and Prospectuses
| 424B3 | Prospectus supplement | May 19, 2026 | ||
| S-1/A | IPO registration | View Diff | May 15, 2026 | |
| S-1 | IPO registration | May 8, 2026 | ||
| 424B5 | Prospectus supplement for primary offering | May 4, 2026 | ||
| S-3 | Shelf registration | Apr 15, 2026 | ||
| 25-NSE | Exchange delisting | Nov 21, 2025 | ||
| 424B5 | Prospectus supplement for primary offering | Nov 5, 2025 | ||
| 424B5 | Prospectus supplement for primary offering | Mar 21, 2025 | ||
| 424B5 | Prospectus supplement for primary offering | Oct 8, 2024 | ||
| S-8 | Registration of securities for employees | Jul 3, 2024 |
Proxies
| DEFA14A | Additional proxy soliciting materials | Jul 6, 2026 | ||
| DEFA14A | Additional proxy soliciting materials | Jul 2, 2026 | ||
| DFAN14A | Additional proxy materials by non-management | Jul 2, 2026 | ||
| DEFA14A | Additional proxy soliciting materials | Jul 1, 2026 | ||
| DEFA14A | Additional proxy soliciting materials | Jun 26, 2026 | ||
| DEFA14A | Additional proxy soliciting materials | Jun 26, 2026 | ||
| DEFA14A | Additional proxy soliciting materials | Jun 26, 2026 | ||
| DEFA14A | Additional proxy soliciting materials | Jun 26, 2026 | ||
| DFAN14A | Additional proxy materials by non-management | Jun 22, 2026 | ||
| DEFA14A | Additional proxy soliciting materials | Jun 16, 2026 |
Other
| EFFECT | Notice of effectiveness | May 19, 2026 | ||
| EFFECT | Notice of effectiveness | May 1, 2026 | ||
| EFFECT | Notice of effectiveness | May 8, 2023 | ||
| CORRESP | Correspondence with SEC | May 3, 2023 | ||
| UPLOAD | Letter from SEC | Mar 23, 2023 | ||
| UPLOAD | Letter from SEC | Jan 29, 2021 | ||
| CORRESP | Correspondence with SEC | Jan 27, 2021 | ||
| UPLOAD | Letter from SEC | Jan 22, 2021 | ||
| CORRESP | Correspondence with SEC | Jan 8, 2021 | ||
| UPLOAD | Letter from SEC | Dec 28, 2020 |